ENCell Co., Ltd. (KOSDAQ:456070)
South Korea
· Delayed Price · Currency is KRW 15,000
-1,190 (-7.35%)
Mar 9, 2026, 3:30 PM KST
ENCell Revenue
ENCell had revenue of 1.55B KRW in the quarter ending September 30, 2025, with 5.25% growth. This brings the company's revenue in the last twelve months to 5.91B, down -44.94% year-over-year. In the year 2024, ENCell had annual revenue of 7.21B, down -31.51%.
Revenue (ttm)
5.91B
Revenue Growth
-44.94%
P/S Ratio
27.84
Revenue / Employee
n/a
Employees
n/a
Market Cap
164.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
| Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
| Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
| Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
| Dec 31, 2020 | 1.40B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 179.98B |
| Vaxcell-Bio Therapeutics | 1.90B |
| iNtRON Biotechnology | 5.56B |
| Genexine | 5.81B |
| EASY BIO,Inc. | 465.24B |
| HLB Therapeutics | 63.25B |
| CG Invites | 18.12B |
| Helixmith | 3.74B |